Management of inherited thrombophilia
- Kenneth A Bauer, MD
Kenneth A Bauer, MD
- Professor of Medicine
- Harvard Medical School
Inherited thrombophilia is a genetic tendency to venous thromboembolism. Factor V Leiden is the most common cause of the syndrome, accounting for 40 to 50 percent of cases. The prothrombin gene mutation, deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias. The total incidence of an inherited thrombophilia in Caucasian subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with approximately 10 percent in controls. (See "Overview of the causes of venous thrombosis", section on 'Inherited thrombophilia'.)
Management issues related to thromboembolism in patients with inherited thrombophilia (eg, factor V Leiden, prothrombin gene mutation, inherited deficiency of proteins S, C, or antithrombin) are reviewed here.
The usefulness of screening for these conditions in various asymptomatic populations and the value of screening in patients presenting with thrombosis are discussed separately. (See "Screening for inherited thrombophilia in asymptomatic individuals".)
Separate topics discuss the presentation and diagnosis of specific thrombophilias. (See "Factor V Leiden and activated protein C resistance" and "Antithrombin deficiency" and "Protein C deficiency" and "Protein S deficiency" and "Prothrombin G20210A mutation inherited thrombophilia".)
INITIAL TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM
Overview of acute VTE treatment in inherited thrombophilias — The initial management of acute thromboembolic disease in patients with inherited thrombophilia (eg, factor V Leiden, prothrombin gene mutation, protein S deficiency) is not different from that in patients without a thrombophilic risk factor.
- Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112:4432.
- Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77:416.
- Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317:991.
- Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104:659.
- De Stefano V, Mastrangelo S, Schwarz HP, et al. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993; 70:247.
- Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.
- Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166:729.
- Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009; 301:2472.
- Baglin C, Brown K, Luddington R, Baglin T. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group. Br J Haematol 1998; 100:764.
- Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293:2352.
- Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ 1998; 316:95.
- Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89:1963.
- Allaart CF, Rosendaal FR, Noteboom WM, et al. Survival in families with hereditary protein C deficiency, 1820 to 1993. BMJ 1995; 311:910.
- van Boven HH, Vandenbroucke JP, Westendorp RG, Rosendaal FR. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 77:452.
- Rosendaal FR, Heijboer H, Briët E, et al. Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet 1991; 337:260.
- Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135:367.
- De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801.
- Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. QJM 2001; 94:365.
- Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998; 128:270.
- Wåhlander K, Larson G, Lindahl TL, et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost 2002; 87:580.
- INITIAL TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM
- Overview of acute VTE treatment in inherited thrombophilias
- Antithrombin deficiency
- Protein C deficiency
- - Screening
- - Anticoagulation with vitamin K antagonists
- LONG-TERM THERAPY TO PREVENT RECURRENCE
- Minimum period of treatment
- Risk of recurrence
- Argument against long-term therapy
- Indefinite anticoagulation
- SPECIAL SCENARIOS
- - Surgery overview
- - Surgery: Factor V Leiden
- - Surgery: Antithrombin deficiency
- Patients with no thrombosis history
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS